Liso-cel CAR-T cost-effective as second-line treatment for advanced lymphoma

Researchers found lisocabtagene maraleucel to be a cost-effective second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma, study findings published in Blood Advances showed.
The analysis is a first-of-its-kind assessment of the chimeric antigen receptor T-cell therapy’s cost-effectiveness while also incorporating health care expenses, societal productivity losses and patient quality of life, according to researchers.
“In our study, we incorporated the often-overlooked societal costs associated with cancer treatment, which are typically

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart